



NEWS RELEASE

Cognetivity Neurosciences Announces Successful Filing of Audited Annual Financial Statements and Lifting of Management Cease Trade Order

Vancouver, British Columbia, June 6, 2022 – Cognetivity Neurosciences Ltd. (“Cognetivity” or the “Company”) (CSE: CGN) (OTCQB: CGNSF) (FRA: 1UB), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that its management cease trade order (“MCTO”) was lifted effective immediately following the filing on SEDAR on June 3, 2022 of the Company’s audited annual financial statements and accompanying management’s discussion and analysis for the fiscal year ended January 31, 2022. The slight delay to the filing was caused by the rapid increase in Cognetivity’s growth and the accompanying increase in the number of transactions, which were quickly resolved and approved by the Company’s auditors.

Cognetivity applied to the applicable securities regulatory authorities and received an MCTO that applied only to the Chief Executive Officer and Chief Financial Officer of the Company, precluding them from trading securities of the Company, and was in effect until the audited annual financial statements and accompanying management’s discussion and analysis were filed on or before June 10, 2022, which was successfully completed on June 3, 2022.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s CognICA™ uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The CognICA™ is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.

For more information, please visit: www.cognetivity.com or contact: info@cognetivity.com

For media enquiries, please contact: Josh Stanbury | josh@sispr.co | 416-628-7441

ON BEHALF OF THE BOARD OF DIRECTORS

“Sina Habibi”

Sina Habibi

Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS

Certain statements included in this news release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "assume" "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Cognetivity Neurosciences Ltd.